Brought to you by 
NeurogesX licenses neuropathic pain treatments to Astellas; sublicensed
20 Dec 2016
Executive Summary
Astellas Pharma Europe has received exclusive rights to sell pain management company NeurogesX's newly approved transdermal capsaicin patch Qutenza in the European Economic Area that includes all EU members plus Iceland, Norway, Liechtenstein, Switzerland, and some Eastern European, Middle Eastern, and African countries. NeurogesX also gave Astellas an option to co-develop its Phase I neuropathic pain candidate NGX1998 (topical liquid capsaicin) and exclusively market it in the same territories.
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
-
Drug Delivery
- Topical Delivery
- Transdermal
-
Drug Delivery
Deal Status
- Final
Deal Type
-
Alliance
- Includes Contract
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
NeurogesX licenses neuropathic pain treatments to Astellas; sublicensed
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice